Phase 3
N=61
Craving, Binge Eating and Obesity
Binge Eating Disorder · Obesity
Bottom Line
View on ClinicalTrials.gov: NCT00414167 ↗Enrolled (actual)
61
Serious AEs
0.0%
Results posted
Mar 2014
Primary outcome: Primary: Frequency of Binge Eating Episodes — 0.8; 1.0 episodes/week
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- bupropion (Drug); Placebo (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- Female
- Sponsor
- Yale University
- Primary completion
- Mar 2011
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Frequency of Binge Eating Episodes |
0.8; 1.0 | — |
| SECONDARY Percent BMI Loss |
1.8; 0.6 | — |
Summary
This research study is designed to look at the effectiveness of bupropion for reducing binge eating in overweight persons with binge eating problems. Participants in the study will receive either bupropion or placebo ("sugar" pill, inactive medication) as an outpatient for eight weeks. In addition, participants will be given the option to receive 8 weeks of free behavioral weight loss treatment. This treatment, known to be effective for reducing binge eating and helping people lose weight, will be administered following the medication phase and at no cost.
It is expected that compared to placebo, bupropion will produce greater reductions in binge eating.
Eligibility Criteria
Inclusion Criteria
- BMI 25-50
- Able to travel to clinical site (New Haven, CT) for bi-weekly visits.
Exclusion Criteria
- Predisposition to seizures
- History of anorexia or bulimia nervosa
- Current Type I or Type II diabetes mellitus
Data sourced from ClinicalTrials.gov (NCT00414167). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.